← Back to Search

Non-invasive Brain Stimulation

rTMS for ADHD (FAST-ADHD Trial)

N/A
Waitlist Available
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosis of ADHD
8-16 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 5 (a decrease is an improvement)
Awards & highlights

FAST-ADHD Trial Summary

This trial will test whether a treatment called repetitive transcranial magnetic stimulation (rTMS) can reduce the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD).

Who is the study for?
This trial is for children aged 8-16 with ADHD, an IQ over 80, and stable on current medication for at least 3 months. They must speak English to give consent. It's not suitable for those with autism, bipolar disorder, psychosis, mania or a history of certain brain treatments or metal implants.Check my eligibility
What is being tested?
The study is examining the effectiveness of repetitive transcranial magnetic stimulation (rTMS) in reducing ADHD symptoms compared to standard treatment options.See study design
What are the potential side effects?
Possible side effects of rTMS include discomfort at the stimulation site, headache, lightheadedness, seizures (very rare), and temporary hearing changes due to the noise during treatment.

FAST-ADHD Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with ADHD.
Select...
I am between 8 and 16 years old.
Select...
I am between 8 and 16 years old.

FAST-ADHD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 5 (a decrease is an improvement)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 5 (a decrease is an improvement) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Conners-3 Parent Rating Scale
Secondary outcome measures
GABA Concentration
Glutamate Concentration

FAST-ADHD Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active rTMSExperimental Treatment1 Intervention
Active repetitive TMS parameters will be intensity 120% resting motor threshold (RMT), 40 pulses over 4 seconds (frequency 10Hz), inter-trial interval of 26 seconds, 75 trains, 3000 pulses/session to the right superior frontal gyrus, duration of 37.5 minutes per session.
Group II: Sham rTMSPlacebo Group1 Intervention
For sham rTMS, set-up, duration, and sound (i.e. clicking sound) will be the same, but no magnetic field will be emitted from the rTMS coil.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
rTMS
2016
Completed Phase 3
~840

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
791 Previous Clinical Trials
868,704 Total Patients Enrolled

Media Library

rTMS (Non-invasive Brain Stimulation) Clinical Trial Eligibility Overview. Trial Name: NCT04532190 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Research Study Groups: Active rTMS, Sham rTMS
Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial 2023: rTMS Highlights & Side Effects. Trial Name: NCT04532190 — N/A
rTMS (Non-invasive Brain Stimulation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04532190 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could I potentially qualify to engage in this trial?

"A total of 30 people, aged between 8 and 16 years old suffering from attention deficit disorder can be enrolled in this study. Candidates should have an IQ above 80 and remain stable on the same medication for a duration of at least 3 months prior to participating."

Answered by AI

Are there any vacancies left in this clinical research endeavor?

"As indicated on clinicaltrials.gov, this trial is no longer enrolling patients. The study was first posted in August of 2022 and last edited in February of the same year. Despite that, there are 1057 different studies actively recruiting across multiple locations at present."

Answered by AI

Can individuals aged sixty and above partake in this medical research?

"The boundaries for enrolment are clear - 8 is the minimum age requirement and 16 is the maximum."

Answered by AI

Who else is applying?

What state do they live in?
New York
Pennsylvania
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
Finding Alternatives to Standard Treatment for Attention-Deficit Hyperactivity Disorder
Frank MacMaster, PhD 2022. "Finding Alternatives to Standard Treatment for Attention-Deficit Hyperactivity Disorder". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04532190.
~15 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top